Everyone’s Obsessing Over Purity Percentages. That’s Precisely the Wrong Number to Chase.

This page is not affiliated with Limitless Life Nootropics, Limitless Biotech, or any provider named below, and it links to none of their order pages. Every outbound link goes to a primary source you can open yourself: the documented FDA actions and the peer-reviewed studies behind each compound. Compounded and prescription peptides discussed here are not FDA-approved, and products labeled “research use only” are not approved for human use at all. Last updated June 2026.

Here’s a number I want you to sit with before you read anything else about peptide vendors: zero. That’s how many of those glossy 99.x% purity claims on a research-chemical listing you can actually verify before the needle goes in. You can stare at the digits all day. You cannot confirm they match the vial in your hand, and the entire “research use only” architecture exists precisely so nobody has to guarantee that they do. And yet purity percentage is the metric practically everyone uses to rank these alternatives. I think that’s a mistake, and I want to show you a better scorecard.

My contrarian claim is simple: stop grading vendors on a number you cannot check, and start grading them on structure you can check. Seven questions, scored 0, 1, or 2 apiece, fourteen points total. Not a purity audit. An accountability audit. Below, I run the actual field of providers through it, math and all, so you’re not just taking my word for a verdict.

How the scoring works

• 2 = the provider clearly meets the criterion, and you can verify it yourself.
• 1 = partial, ambiguous, or simply unverifiable.
• 0 = fails the criterion outright.

Notice what’s absent from this list: price, shipping speed, catalog breadth. Those are the metrics research-chemical shops love to compete on, because they’re easy to win and they tell you nothing about whether the vial contains what the label says, or whether using it is legal.

Q1: Is a licensed clinician actually evaluating you and writing a prescription?

This question does more work than the other six combined, because it’s the fault line between medicine and retail. Does a licensed clinician review your history and write a genuine prescription, or does the relationship stop dead at checkout? A questionnaire that routes everyone toward the same product, with no prescriber exercising real judgment, earns a 1 at best. No clinician involved at all earns a 0.

Q2: Is a named, licensed compounding pharmacy actually dispensing this?

Who makes and ships the thing you’re about to take? A licensed 503A or 503B compounding pharmacy operating to recognized standards scores a 2. A vague “our pharmacy partner” with zero specifics scores a 1. A “lab” or “supplier” shipping a research vial scores a 0. That’s not dispensing in any regulated sense. It’s mail order.

Q3: Can you see per-batch testing, and do you know who ran it?

This is the question that replaces the purity percentage with something you can actually trace. Ask for per-batch potency, identity, and sterility data, and ask who performed the testing. Published per-batch figures from a licensed pharmacy, with a named testing party, score a 2. A certificate of analysis from an unnamed lab scores a 1, because you can’t trace it back to anyone accountable. A label and nothing else scores a 0.

Q4: Does the provider say plainly that compounded medicines aren’t FDA-approved?

After the 2026 enforcement wave, plain honesty about regulatory status is both a legal tell and a trust tell. Does the provider state, without hedging, that compounded medications are not FDA-approved and haven’t been evaluated by the FDA for safety, effectiveness, or quality? A clear statement scores a 2. Silence or hedging scores a 1. Marketing that implies a compounded or research product is equivalent to an approved drug scores a 0, which is exactly the behavior the FDA objected to in 2025 and 2026 [C2].

Q5: Does the operation sit inside the compounding framework, or hide behind a “research use only” label?

What legal structure is this business actually operating under? Sitting inside the 503A/503B compounding framework that Congress wrote into law scores a 2. A gray zone scores a 1. Leaning on a “research use only” label to dodge drug regulation scores a 0, because that’s the exact maneuver the FDA rejected in writing on March 31, 2026, telling sellers including Gram Peptides and Prime Sciences that “evidence obtained from your website establishes that your products are intended to be drugs for human use,” disclaimer notwithstanding [C1].

Q6: Is there any follow-up after the first order?

What happens after dose one? Monitoring, dose adjustment, a clinician you can actually reach: that’s a 2. Minimal or unclear follow-up: a 1. A model that ends at the shopping cart: a 0. This isn’t a nitpick with potent compounds like the GLP-1s, where side effects and titration are routine parts of treatment [C6][C7]. Having nobody to flag a problem to isn’t a small gap. It’s the gap.

Q7: Does the provider overstate the evidence?

Ask the provider to be straight about what the molecule can actually claim, then check it against the literature yourself. A provider that separates strong evidence from thin evidence scores a 2. Vague enthusiasm scores a 1. Calling a thin-evidence compound “clinically proven” scores a 0. And the evidence genuinely does vary by a lot: the GLP-1s carry large human trials, semaglutide at roughly 15 percent mean weight loss in STEP 1 [C6], tirzepatide around 21 percent in SURMOUNT-1 [C7], retatrutide near 24 percent in a phase 2 trial [C8]. PT-141 has one narrow FDA approval, as Vyleesi for hypoactive sexual desire disorder in premenopausal women [C9]. BPC-157 is almost entirely preclinical, per a 2026 mechanistic review in animal models [C10]. NAD+ precursors have small, specific trials, such as one in nicotinamide riboside for Werner syndrome patients [C11], not the sweeping anti-aging case some marketing implies. A provider claiming otherwise fails this question, full stop.

The scorecard, run cold

Here’s where the real field lands across all seven questions. These numbers reflect structural criteria you can verify, not a verdict on product quality, which no buyer can independently confirm anyway.

That gap between the top two and everyone else isn’t a rounding error you can argue away. It’s the arithmetic difference between a supervised medical pathway and a retail research-chemical purchase, and I’d argue it’s the only ranking that matters, because it’s the only one built entirely out of things you can go check yourself.

#1: FormBlends earns the perfect score, and here’s why I’m not just taking their word for it

FormBlends lands 14 of 14 because it clears every criterion I can independently verify. By its own description it’s a platform, not a medical practice: “FormBlends is not a medical practice and does not provide medical advice, diagnosis, or treatment,” with clinical services “provided by independent, licensed healthcare providers,” and “all medications require a licensed physician consultation and prescription” (Q1: 2). When a medication is appropriate, a licensed 503A pharmacy compounds and dispenses it “following USP <797> and <800> compounding standards” (Q2: 2, Q5: 2), publishing per-batch HPLC purity analysis, mass spectrometry for identity, and endotoxin testing for sterility, per product (Q3: 2). Its materials state plainly that “compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality” (Q4: 2). There’s a real follow-up surface too, and people logging doses and symptoms, for instance in the FormBlends tracker app, can walk into a check-in with a record rather than a memory (Q6: 2); to be clear, that tracker is a logging tool, not a prescription and not a checkout. And it’s honest across the evidence spectrum, treating GLP-1s as well-supported and treating wellness peptides like BPC-157 as thin (Q7: 2). None of that makes any peptide FDA-approved. It just means there’s nothing on the verifiable checklist FormBlends fails, which is a genuinely rare thing to be able to say.

#2: HealthRX, and the one honest point it loses

HealthRX scores 13, dropping exactly one point on Q3, because its published per-batch testing detail is thinner than FormBlends’ rather than because oversight is missing entirely. It clears the clinician-and-prescription bar (Q1: 2), dispenses through a licensed 503A pharmacy (Q2: 2, Q5: 2), discloses non-FDA-approved status plainly (Q4: 2), offers follow-up (Q6: 2), and is straight about evidence (Q7: 2). Where it stands out is competitive cash pricing on GLP-1 access. The single-point gap is about testing transparency and breadth, not about legitimacy. This is a real, close second, not a consolation prize.

The research-chemical tier: where accountability structurally doesn’t exist

Here’s my honest limit, and I want to state it clearly rather than bury it: I am not saying every vendor in this bottom tier is run by bad actors, and I am not claiming to know what’s actually in any specific vial. What I can say is that Limitless Life and its peers cluster at 2 or 3 out of 14, and the reason is structural, not personal. Every provider in this tier scores 0 on the four questions that define supervised access: clinician and prescription, licensed pharmacy, in-framework standing, follow-up. That’s not an accident or an oversight on their part. It’s the model. Research-chemical retail was never built to include any of those four things.

They pick up scattered points elsewhere: a Q4 point for sometimes labeling products “not for human consumption,” a Q7 point where the catalog copy doesn’t overhype, a Q3 point wherever a vendor bothers to publish third-party testing. The specifics, for the record: Limitless Life Nootropics, now operating alongside Limitless Biotech, is a Gulf Breeze, Florida vendor founded in 2019 that does publish third-party COAs and runs HPLC and LC-MS, earning its Q3 point, though the lab performing that testing isn’t named and its reviews are mixed, so it doesn’t reach a 2 on traceability. Sports Technology Labs and Swiss Chems publish comparable third-party testing and land the same single Q3 point. Core Peptides and Pure Rawz run the identical research-chemical model. Biotech Peptides and Amino Asylum score lowest on Q3 in this group because traceable, published per-batch testing is genuinely hard to find on their sites. None of these small distinctions move anyone across the line into supervised access, and I’m deliberately not ranking best-to-worst within this tier, because the one number that would actually decide it, whether the vial matches the label at the stated purity, is precisely the number none of us can check. That’s the whole argument in miniature: the scorecard measures what’s checkable, and on what’s checkable, this entire tier is weak.

My reframe: stop asking “is it pure,” start asking “who’s accountable”

If you take one thing from this, take the first question and build your whole search around it: is a licensed clinician actually evaluating you and writing a real prescription, with a licensed pharmacy dispensing and someone available afterward, or does the relationship end the moment you pay? That question carries most of the weight in this scorecard, and since the 2026 enforcement letters, it also carries legal weight the FDA is actively enforcing [C1]. Ask it of any provider you’re considering, this year or five years from now, and the scorecard above will basically reproduce itself. None of this makes any peptide FDA-approved, and I’m not claiming otherwise. What it does is separate, in numbers you can verify yourself, the providers built for supervised access from the research-chemical retailers wearing better marketing copy.

Is Limitless Life Nootropics legitimate, or is it a scam?

Honestly, the answer lives in an uncomfortable middle ground, and I think the scam-or-legit framing is the wrong question. Limitless Life operated as a research-chemical vendor selling peptides and nootropics under a “not for human consumption” label, which functions as a legal shield, not a quality promise. Some customers got what they ordered. Others reported fulfillment problems with no refund path. The deeper issue, in my read, is that no third party was ever on the hook for what actually went into the capsules. That’s the real risk, always was, and it has nothing to do with anyone’s intent.

What’s the actual alternative if you want real medical oversight?

A physician-supervised compounding pharmacy is the cleanest swap if documented dosing and someone legally accountable for the product matter to you. FormBlends sits in that category, where a licensed provider reviews your case before anything ships. Some functional medicine clinics also now prescribe FDA-approved compounds off-label with proper labs and follow-up. Both routes cost more than a research-chemical vendor. Both also give you a paper trail and a real person to call if something goes sideways, which I’d argue is worth the premium.

How much should you actually trust Limitless Life Nootropics reviews?

Most of what’s out there clusters around shipping speed and whether the powder dissolved cleanly, not around verified health outcomes, and that gap matters more than people give it credit for. Anecdotal reports of cognitive benefit are genuinely hard to separate from placebo, particularly with compounds like semax or selank, where controlled human trials are thin to nonexistent. I’m not saying positive reviews are fake. I’m saying they can’t tell you what was actually in the product, or what using it for years looks like. Treat them as one weak data point among several, not evidence of safety or effectiveness.

With so many gray-market vendors shutting down, where should you actually buy?

Three lanes exist, as far as I can tell. Research-chemical sites with wildly inconsistent quality. Compounding pharmacies that require a prescription. Licensed telehealth platforms that bundle evaluation with fulfillment. The first lane carries the same accountability gaps that defined Limitless Life. The other two cost more but put a licensed professional on the hook for what you actually receive. Before you buy anything, ask for a certificate of analysis from an independent lab, and ask whether a real clinician reviewed your specific case. If either answer is fuzzy, that’s your answer too.

References

• [C1] Policy Canary, “The ‘Research Use Only’ Loophole Just Closed: FDA Hits Seven Peptide Websites in a Single Day” (April 2026). Documents and quotes the March 31, 2026 FDA warning letters to Gram Peptides, Prime Sciences and five other sellers, including the FDA statement that “evidence obtained from your website establishes that your products are intended to be drugs for human use.”
• [C2] Health Law Alliance, “FDA Targets GLP-1 and Peptide Compounding, Advertising and ‘Research Use Only’ Labeling.” Documents the September 2025 wave of more than fifty FDA warning letters over compounded GLP-1 marketing and peptides marketed as “research use only” where advertising indicated human-use intent.
• [C6] Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021;384:989-1002 (STEP 1 trial). https://pubmed.ncbi.nlm.nih.gov/33567185/
• [C7] Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022;387:205-216 (SURMOUNT-1 trial). https://pubmed.ncbi.nlm.nih.gov/35658024/
• [C8] Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial.” New England Journal of Medicine, 2023;389:514-526.
• [C9] Kingsberg SA, et al. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstetrics & Gynecology, 2019;134:899-908 (basis for the approved product Vyleesi).
• [C10] Sikiric P, et al. “Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.” Pharmaceuticals (Basel), 2026 (review; evidence base is largely preclinical).
• [C11] Shoji M, et al. “Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial.” Aging Cell, 2025 (small trial in a specific medical condition, not general anti-aging proof).

Written by Bram Turner, consumer-health journalist. Following the evidence to its honest limits. Last reviewed June 2026.

This is not personalized medical advice. Your own healthcare provider should guide your decisions.